Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results![The Byzantine Logic of Patent Law Jurisprudence: Patent Protection for Dosage Regimes Revisited](/images/research/c7cda792-7a14-401c-8a9e-3d7781969b01/small/14965.jpg)
research The Byzantine Logic of Patent Law Jurisprudence: Patent Protection for Dosage Regimes Revisited
UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.
![Recent European Legal Developments on Second Medical Uses and Dosage Regimes](/images/research/e8ad4951-ab08-446b-8ee8-5bb880c309f2/small/14685.jpg)
research Recent European Legal Developments on Second Medical Uses and Dosage Regimes
European patent law now allows patents for new uses and dosages of known drugs, but protection scope is unclear.
![Generic Competition And Pharmaceutical Patent Strategies: A Sequel](/images/research/ecca3ed2-36eb-4917-9dbf-7e1590fd5483/small/15050.jpg)
research Generic Competition And Pharmaceutical Patent Strategies: A Sequel
The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
![UK High Court Revokes Escitalopram Patent; Validity of Second Medical Use Claims Based on Dosage Regimes; Stay of Proceedings Pending EPO Opposition](/images/research/f0e616ea-3538-4e85-9d51-700dbb5bb6ad/small/15153.jpg)
research UK High Court Revokes Escitalopram Patent; Validity of Second Medical Use Claims Based on Dosage Regimes; Stay of Proceedings Pending EPO Opposition
The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.
![Healthcare Innovation and Patent Law’s Pharmaceutical Privilege: Is There a Pharmaceutical Privilege? And If So, Should We Remove It?](/images/research/8106fdec-be9f-435c-91bf-8f16fe4566c0/small/13815.jpg)
research Healthcare Innovation and Patent Law’s Pharmaceutical Privilege: Is There a Pharmaceutical Privilege? And If So, Should We Remove It?
The document suggests reevaluating the patent system to ensure public benefits from pharmaceutical privileges and to encourage more significant innovations.
Community Join
5 / 143 results![The story of RU58841/ PSK3841](/images/research/7fbfa1bf-2649-4c7a-b184-390523d2e635/small/10192.jpg)
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community Dermatologist told me to quit fin after turning 40
A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.
community Guide: How to EASILY get prescription oral minoxidil
The conversation provides a six-step guide on how to get a prescription for oral minoxidil (OM) for hair loss by finding a supportive dermatologist, even if they are not local, and preparing a case for its use during a virtual consultation. The guide emphasizes the importance of research, insurance considerations, and the potential for initial hair shedding with OM treatment.
community Male (24) Using Dutasteride Since 2020 – Concerns About Having Kids
A 24-year-old male using dutasteride for hair loss is worried about its effects on fertility and future children's health. Users advise consulting a doctor, possibly switching to finasteride, or stopping dutasteride before conception due to its impact on sperm count.